BR112022023834A2 - Composto duplo-agonista para os receptores de glp-1 e gip e aplicação do mesmo - Google Patents
Composto duplo-agonista para os receptores de glp-1 e gip e aplicação do mesmoInfo
- Publication number
- BR112022023834A2 BR112022023834A2 BR112022023834A BR112022023834A BR112022023834A2 BR 112022023834 A2 BR112022023834 A2 BR 112022023834A2 BR 112022023834 A BR112022023834 A BR 112022023834A BR 112022023834 A BR112022023834 A BR 112022023834A BR 112022023834 A2 BR112022023834 A2 BR 112022023834A2
- Authority
- BR
- Brazil
- Prior art keywords
- glp
- application
- agonist compound
- gip
- double
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010472577 | 2020-05-29 | ||
| CN202110335100 | 2021-03-29 | ||
| PCT/CN2021/096568 WO2021239082A1 (zh) | 2020-05-29 | 2021-05-28 | Glp-1和gip受体双重激动剂化合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022023834A2 true BR112022023834A2 (pt) | 2022-12-27 |
Family
ID=78745631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022023834A BR112022023834A2 (pt) | 2020-05-29 | 2021-05-28 | Composto duplo-agonista para os receptores de glp-1 e gip e aplicação do mesmo |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230190879A1 (https=) |
| EP (1) | EP4159750A4 (https=) |
| JP (1) | JP2023526973A (https=) |
| KR (1) | KR20230018395A (https=) |
| CN (3) | CN114222755B (https=) |
| AU (1) | AU2021278157A1 (https=) |
| BR (1) | BR112022023834A2 (https=) |
| CA (1) | CA3180215A1 (https=) |
| MX (1) | MX2022014368A (https=) |
| TW (1) | TWI910174B (https=) |
| WO (1) | WO2021239082A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| US20250115654A1 (en) * | 2021-11-12 | 2025-04-10 | Fujian Shengdi Pharmaceutical Co., Ltd. | Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof |
| WO2023207106A1 (zh) * | 2022-04-29 | 2023-11-02 | 苏州星洲生物科技有限公司 | Glp-1/gip受体共激动剂、包含其的药物组合物及其用途 |
| EP4556487A1 (en) * | 2022-07-13 | 2025-05-21 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Glp-1/gip dual agonist, and preparation method therefor and use thereof |
| CN115806593B (zh) * | 2022-09-23 | 2023-09-05 | 成都普康生物科技有限公司 | 一种脂肪酸链修饰的双受体激动剂及其用途 |
| CN116120425A (zh) * | 2022-12-27 | 2023-05-16 | 南京赛诺生物技术有限公司 | 一种glp-1/gip受体双重激动剂及其应用 |
| CN118056839B (zh) * | 2023-01-17 | 2024-11-29 | 广东众生睿创生物科技有限公司 | 带有修饰结构的多肽及其应用 |
| CN118684758A (zh) * | 2023-03-23 | 2024-09-24 | 上海民为生物技术有限公司 | 肠促胰岛素类似物及其应用 |
| CN116496361B (zh) * | 2023-06-25 | 2023-09-15 | 北京科翔中升医药科技有限公司 | 氘代模拟肽gip和glp-1双受体激动剂药物及用途 |
| TW202529797A (zh) * | 2023-12-12 | 2025-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途 |
| WO2025242218A1 (zh) * | 2024-05-24 | 2025-11-27 | 上海翰森生物医药科技有限公司 | 一种多肽激动剂，其制备方法及医药用途 |
| CN120081924A (zh) * | 2024-07-11 | 2025-06-03 | 中国药科大学 | Glp-1r受体激动多肽化合物及其用途 |
| CN119390784A (zh) * | 2024-07-11 | 2025-02-07 | 中国药科大学 | 一种双激动多肽化合物及其医药用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6006118B2 (ja) * | 2009-12-16 | 2016-10-12 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アナログ及び誘導体 |
| US9453062B2 (en) * | 2011-06-10 | 2016-09-27 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| CN104583232B (zh) * | 2012-06-21 | 2018-04-13 | 印第安纳大学研究及科技有限公司 | 展现gip受体活性的胰高血糖素类似物 |
| AU2013366692B2 (en) * | 2012-12-21 | 2017-11-23 | Sanofi | Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists |
| CN108271356A (zh) * | 2014-09-24 | 2018-07-10 | 印第安纳大学研究及科技有限公司 | 肠降血糖素-胰岛素缀合物 |
| CN107108715A (zh) * | 2014-10-24 | 2017-08-29 | 默沙东公司 | 胰高血糖素和glp‑1受体的共激动剂 |
| WO2016131893A1 (en) * | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
| US10946074B2 (en) * | 2016-03-03 | 2021-03-16 | Novo Nordisk A/S | GLP-1 derivatives and uses thereof |
| CN112351994B (zh) * | 2019-04-11 | 2024-06-07 | 江苏豪森药业集团有限公司 | 一种多受体激动剂及其医药用途 |
| CN111825758B (zh) * | 2019-04-19 | 2024-11-22 | 上海翰森生物医药科技有限公司 | Glp-1和gip共激动剂化合物 |
-
2021
- 2021-05-28 CN CN202180004912.4A patent/CN114222755B/zh active Active
- 2021-05-28 TW TW110119502A patent/TWI910174B/zh active
- 2021-05-28 CN CN202410666887.1A patent/CN118754965A/zh active Pending
- 2021-05-28 MX MX2022014368A patent/MX2022014368A/es unknown
- 2021-05-28 KR KR1020227043237A patent/KR20230018395A/ko active Pending
- 2021-05-28 WO PCT/CN2021/096568 patent/WO2021239082A1/zh not_active Ceased
- 2021-05-28 BR BR112022023834A patent/BR112022023834A2/pt unknown
- 2021-05-28 AU AU2021278157A patent/AU2021278157A1/en active Pending
- 2021-05-28 JP JP2022571299A patent/JP2023526973A/ja active Pending
- 2021-05-28 CN CN202410663771.2A patent/CN118530333A/zh active Pending
- 2021-05-28 CA CA3180215A patent/CA3180215A1/en active Pending
- 2021-05-28 US US17/927,304 patent/US20230190879A1/en active Pending
- 2021-05-28 EP EP21812549.0A patent/EP4159750A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118530333A (zh) | 2024-08-23 |
| MX2022014368A (es) | 2022-12-15 |
| EP4159750A1 (en) | 2023-04-05 |
| JP2023526973A (ja) | 2023-06-26 |
| TW202144393A (zh) | 2021-12-01 |
| AU2021278157A1 (en) | 2022-11-24 |
| WO2021239082A1 (zh) | 2021-12-02 |
| CN114222755B (zh) | 2024-06-11 |
| US20230190879A1 (en) | 2023-06-22 |
| CN118754965A (zh) | 2024-10-11 |
| CN114222755A (zh) | 2022-03-22 |
| CA3180215A1 (en) | 2021-12-02 |
| TWI910174B (zh) | 2026-01-01 |
| EP4159750A4 (en) | 2023-10-18 |
| KR20230018395A (ko) | 2023-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022023834A2 (pt) | Composto duplo-agonista para os receptores de glp-1 e gip e aplicação do mesmo | |
| MX2021000793A (es) | Compuestos coagonistas de gip/glp1. | |
| PE20220938A1 (es) | Compuestos agonistas de gipr | |
| BR112021020071A2 (pt) | Compostos agonistas duplos do receptor de glp-1 e gip e uso dos mesmos | |
| AR067555A1 (es) | Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal | |
| AR098736A1 (es) | Análogos del péptido exendina-4 como agonistas duales del receptor del glp-1 / gip (péptido similar al glucagón tipo 1 / polipéptido insulinotrópico dependiente de glucosa) | |
| BR112022009396A2 (pt) | Análogos de incretina e usos dos mesmos | |
| AR121093A1 (es) | Compuestos coagonistas de gip / glp1 | |
| PE20211417A1 (es) | Analogos novedosos de glp-1 | |
| AR072159A1 (es) | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad | |
| PE20230819A1 (es) | Composiciones y usos de glp-1 | |
| AR098737A1 (es) | Agonistas duales del receptor de glp-1 / gip | |
| MX2023000303A (es) | Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral. | |
| BR112012017949A2 (pt) | composição farmacêutica para o tratamento de uma síndrome metabólica | |
| Owolabi et al. | In vitro and in vivo insulinotropic properties of the multifunctional frog skin peptide hymenochirin-1B: a structure–activity study | |
| MX2023014771A (es) | Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso. | |
| MX2022003251A (es) | Anticuerpo contra gipr y su proteina de fusion con glp-1, y composicion farmaceutica y aplicacion de los mismos. | |
| JOP20230224A1 (ar) | التركيبات المحتوية على نظائر الإنكريتين واستخداماتها | |
| CL2025000088A1 (es) | Agonista dual de glp-1/gip, método de preparación y uso del mismo | |
| BR112022012499A2 (pt) | Peptídeo, composição, métodos para tratar um paciente e para tratar uma doença, e, uso de um peptídeo | |
| TH2001005828A (th) | Glp-1 อนาล็อกชนิดใหม่ | |
| TH1701002228A (th) | อะโกนิสต์ร่วมของกลูคากอนและ glp-1 รีเซปเตอร์ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) |